# Efficacy of Dupilumab in a Young Woman with Refractory Cutaneous Lichen Planus: A Case-Based Review

## TL;DR

A young woman with long-standing cutaneous lichen planus achieved full remission after two years of dupilumab treatment, suggesting its potential as a new therapy.

## Contribution

This case study demonstrates the efficacy of dupilumab in treating refractory cutaneous lichen planus, highlighting Th2 pathway targeting as a novel therapeutic approach.

## Key findings

- Dupilumab treatment led to full remission in a 26-year-old woman with longstanding cutaneous lichen planus.
- The patient experienced resolution of severe pruritus and skin lesions after two years of dupilumab therapy.
- The case suggests that targeting the Th2 pathway may be effective in treating refractory CLP.

## Abstract

Background: Cutaneous lichen planus (CLP) is a chronic inflammatory T cell-mediated disease driven by a mixed Th1 and Th2 lymphocyte population, for which many of the currently available treatments have poor efficacy. Aim: The aim of this study was to indicate the clinical success of dupilumab administration after two years of treatment in a case of longstanding CLP and to perform a review of the medical literature related to the use of dupilumab in different dermatologic settings and in CLP. Case presentation: One 26-year-old woman with a previous history of atopic dermatitis had a long-lasting skin condition, referred to as a suspected lichen, which started when she was 7 years old. Her disease exhibited a relapsing–remitting course with severe bouts of pruritus over a very long period. The final histological diagnosis of CLP was confirmed at the age of 26. Starting dupilumab (injected subcutaneously at a dose of 600 mg followed by a maintenance dose of 300 mg every two weeks) resolved the skin scenery of this patient, who is currently in full remission. Conclusions: The remarkable recovery from CLP obtained via treatment with dupilumab in this single-patient case study emphasizes the potential therapeutic implications of targeting the Th2 pathway in this skin disorder.